Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05039801 · ClinicalTrials.gov registry record · Phase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

A Phase 1 study of Advanced Malignant Solid Neoplasm and Clinical Stage IV Cutaneous Melanoma AJCC v8, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT05039801 is a Phase 1 study of Advanced Malignant Solid Neoplasm and Clinical Stage IV Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 54 participants, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05039801, a Phase 1 study of Advanced Malignant Solid Neoplasm and Clinical Stage IV Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Conditions Studied

Advanced Malignant Solid Neoplasm Clinical Stage IV Cutaneous Melanoma AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Advanced Melanoma Chondrosarcoma Advanced Endometrial Carcinoma Advanced Head and Neck Squamous Cell Carcinoma Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Advanced Ovarian Clear Cell Adenocarcinoma

Interventions

  • DRUG Paclitaxel
  • BIOLOGICAL Bevacizumab
  • DRUG Glutaminase-1 Inhibitor IACS-6274
  • DRUG Capivasertib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2021-09-09
Est. Completion 2026-05-29
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05039801

The ClinicalTrials.gov registry entry for NCT05039801 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (69% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.

NCT05039801 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05039801 about?

NCT05039801 is a clinical study titled "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors". To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

What is the current status of trial NCT05039801?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-09-09. Estimated completion is 2026-05-29.

What conditions does trial NCT05039801 study?

This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Advanced Melanoma, Chondrosarcoma.

What interventions are being tested in trial NCT05039801?

The interventions under investigation include: Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Glutaminase-1 Inhibitor IACS-6274 (DRUG), Capivasertib (DRUG).

Who is sponsoring clinical trial NCT05039801?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05039801 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Malignant Solid Neoplasm

All registered trials for this condition

Clinical Stage IV Cutaneous Melanoma AJCC v8

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.